EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q1 | -3.31 | $0 | -$7M |
| 2023 Q4 | -3.42 | $162,000 | -$6M |
| 2023 Q3 | -3.36 | $0 | -$8M |
| 2023 Q2 | -4.37 | $0 | -$9M |
| 2023 Q1 | -5.96 | $0 | -$8M |
| 2022 Q4 | -5.57 | $0 | -$7M |
| 2022 Q3 | -5.80 | $0 | -$8M |
| 2022 Q2 | -4.20 | $2M | -$5M |